All In Biotech

Drug Trial Radar · NCT01796301

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy

Last checked: Nov 20, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

436

Actual

Start

Jan 31, 2013

Primary completion

May 14, 2015

Study completion May 14, 2015

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • RomozosumabDrug

    Administered by subcutaneous injection once a month.

  • TeriparatideDrug

    Administered by subcutaneous injection once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)Time frame: Baseline, month 6 and month 12

Locations

50 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Gainesville, Georgia

  • Research Site

    Bethesda, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Córdoba, Córdoba Province, Argentina

  • Research Site

    Genk, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Medellín, Antioquia, Colombia

  • Research Site

    Barranquilla, Atlántico, Colombia

  • Research Site

    Brno, Czechia

  • Research Site

    Ostrava, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Praha 11 - Chodov, Czechia

  • Research Site

    Uherské Hradiště, Czechia

  • Research Site

    Aalborg, Denmark

  • Research Site

    Aarhus C, Denmark

  • Research Site

    Ballerup Municipality, Denmark

  • Research Site

    Esbjerg, Denmark

  • Research Site

    Hillerød, Denmark

  • Research Site

    Hvidovre, Denmark

  • Research Site

    Odense, Denmark

  • Research Site

    Budapest, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Gdynia, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Wroclaw, Poland

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.